2026-05-22T02:49:53Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/182912024-11-28T14:42:45Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Cabezudo-García, Pablo
author
Mena-Vázquez, Natalia
author
Ciano-Petersen, Nicolás L.
author
García-Martín, Guillermina
author
Estivill-Torrús, Guillermo
author
Serrano-Castro, Pedro J.
authoraffiliation
[Cabezudo-García,P; Mena-Vázquez,N; Ciano-Petersen,NL; García-Martín,G; Estivill-Torrús,G; Serrano-Castro,PJ] Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain. [Cabezudo-García,P; Ciano-Petersen,NL; García-Martín,G; Estivill-Torrús,G; Serrano-Castro,PJ] Unidad de Gestión Clínica de Neurociencias, Hospital Regional Universitario de Málaga, Málaga, Spain. [Mena-Vázquez,N] Unidad de Gestión Clínica de Reumatología, Hospital Regional Universitario de Málaga, Málaga, Spain.
2024-02-19T15:26:36Z
2024-02-19T15:26:36Z
2021-03-19
10.3390/brainsci11030392
2076-3425
Brain Sciences
http://hdl.handle.net/10668/4349
33808902
http://hdl.handle.net/20.500.12105/18291
Background: The prevalence of neural autoantibodies in epilepsy of unknown etiology varies among studies. We aimed to conduct a systematic review and meta-analysis to determine the pooled global prevalence and the prevalence for each antibody. Methods: A systematic search was conducted for studies that included prospectively patients ≥16 years old with epilepsy of unknown etiology and systematically determined neural autoantibodies. A meta-analysis was undertaken to estimate pooled prevalence in total patients with a positive result for at least one neural autoantibody in serum and/or cerebrospinal fluid (CSF) and for each autoantibody. Results: Ten of the eleven studies that met the inclusion criteria and a total of 1302 patients with epilepsy of unknown etiology were included in themeta-analysis. The global pooled prevalence (IC95%) was 7.6% (4.6–11.2) in a total of 82 patients with a positive result for any neural autoantibody. None of the controls available in the studies had a positive result. Individual pooled prevalence for each autoantibody was: glycine receptor (GlyR) (3.2%), glutamic acid decarboxylase (GAD) (1.9%), N-methyl-d-aspartate receptor (NMDAR) (1.8%), leucine-rich glioma inactivated-1 protein (LGI1) (1.1%), contactin-2-associated protein (CASPR2) (0.6%) and onconeuronal (0.2%). Conclusions: The pooled prevalence of neural autoantibodies in patients with epilepsy of unknown etiology is small but not irrelevant. None of the controls had a positive result. There was high heterogeneity among studies. In the future, a homogeneous protocol for testing neural autoantibodies is recommended.
eng
Epilepsy
Autoimmune epilepsy
Antibodies
Autoantibodies
Neural autoantibodies
Prevalence
Glutamic acid decarboxylase
Glycine receptor
Epilepsia
Anticuerpos
Autoanticuerpos
Prevalencia
Glutamato descarboxilasa
Receptores de glicina
Prevalence of Neural Autoantibodies in Epilepsy of Unknown Etiology: Systematic Review and Meta-Analysis
review article